“I look forward to continuing our relationship and supporting this very worthy endeavor," said Alex Zapesochny, Executive Vice President, Cardiac Safety at ERT.
PHILADELPHIA (PRWEB) March 19, 2018
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced that it has been recognized by Simon’s Fund with a Big Heart Award. Simon’s Fund is a Philadelphia-based non-profit organization dedicated to raising awareness about the warning signs and conditions that lead to sudden cardiac arrest and death in children.
ERT and its Chief Medical Officer, Robert Kleiman, MD, are being honored for their contributions to the success of Simon’s Fund. Since 2014, every heart screening that Simon’s Fund provides has been equipped with ECG machines donated by ERT. Dr. Kleiman was instrumental in the development of Simon’s Fund’s digital platform, HeartBytes, a first-of-its-kind registry that gathers and disseminates heart screening information to qualified researchers free of charge, for the purpose of advancing life-saving research across the United States.
“We are extremely grateful to ERT and Dr. Kleiman for their ongoing contributions to Simon’s Fund, and for their pioneering work in advancing cardiac safety,” said Darren Sudman, CEO and Co-founder, Simon’s Heart. “ERT has supported us for nearly five years by providing ECG machines for our youth heart screenings, and Bob Kleiman has been a trusted adviser during the development of HeartBytes, our digital cardiac registry of seemingly healthy kids.”
“We are very proud of our association with Simon’s Fund and the great work they do to prevent sudden cardiac arrest, which takes the lives of more than 2,000 U.S. children and adolescents every year,” said Alex Zapesochny, Executive Vice President, Cardiac Safety at ERT. “I look forward to continuing our relationship and supporting this very worthy endeavor.”
For more information on ERT’s expertise in cardiac safety assessment, visit ert.com/cardiac-safety.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2017, ERT supported more than 60% of all FDA drug approvals. Pharma companies, biotechs and CROs have relied on ERT solutions in 13,000+ studies, spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.